Hexa Reports Market Research Reports and Insightful Company Profiles
CNV-1014802 Industry 2015,Share and Size,Trends and Price,Forecast and Market Analysis to 2022
Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile. CNV-1014802 is a novel therapy being developed by Convergence Pharmaceuticals for the treatment of pain associated with entrapment neuropathies, such as lumbosacral radiculopathy and TN. Like CNV2197944, CNV-1014802 was acquired from GSK in 2010 as part of an agreement in which the company acquired an 18% minority equity stake in Convergence Pharmaceuticals. CNV-1014802 is a small molecule that blocks the Nav1.7 sodium channels, which are involved in transmitting pain signals. It was
Hexa Reports Market Research Reports and Insightful Company Profiles demonstrated in experimental models to block the high frequency and spontaneous neuronal firing that is often characteristic of TN. Browse Detail Report with TOC @ http://www.hexareports.com/report/cnv-1014802-neuropathicpain-forecast-and-market-analysis-to-2022/details Scope
Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on CNV-1014802 including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for CNV-1014802 for the top six countries from 2012 to 2022. Sales information covered for the US, France, Germany, Italy, Spain and the UK.
Reasons to buy 1. Understand and capitalize by identifying products that are most likely to ensure a robust return 2. Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain 3. Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 4. Make more informed business decisions from insightful and in-depth analysis of CNV-1014802 performance 5. Obtain sales forecast for CNV-1014802 from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK). Request a Sample copy of This Report @ http://www.hexareports.com/sample/41965 Table of Contents 1 Table of Contents 5 1.1 List of Tables 8 1.2 List of Figures 9 2 Introduction 10 2.1 Catalyst 10 2.2 Related Reports 10 3 Disease Overview 12 3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 14 3.1.1 Painful Diabetic Neuropathy 16 3.1.2 Postherpetic Neuralgia 17 3.1.3 Trigeminal Neuralgia 17
Hexa Reports Market Research Reports and Insightful Company Profiles 3.2 Etiology and Pathophysiology 18 3.2.1 Etiology 19 3.2.2 Pathophysiology 20 4 Disease Management 28 4.1 Diagnosis and Treatment Overview 28 4.1.1 Diagnosis 28 4.1.2 Treatment Overview and Guidelines 35 Browse Full Report @ http://www.hexareports.com/report/cnv-1014802-neuropathic-pain-forecastand-market-analysis-to-2022/details About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States Phone Number 1-800-489-3075 Email Us: sales@hexareports.com Our Website: http://www.hexareports.com/